Persistence with weekly alendronate therapy among postmenopausal women
- 243 Downloads
Although clinical trials indicate that oral bisphosphonates reduce osteoporotic fracture risk, compliance with bisphosphonate therapy in practice is suboptimal, with 1-year discontinuation rates exceeding 50%.
We conducted a retrospective cohort study among female members of a large integrated health care delivery system (Kaiser Permanente of Northern California), age 45 years and older, to determine their persistence with weekly alendronate (defined as continuous use, allowing for a refill gap of 60 days), predictors of discontinuation, and subsequent osteoporosis therapy. We also examined the effect of varying the refill gap from 30 to 120 days on the discontinuation rate. From 2002 through 2003, we identified 13,455 women (age 68.8±10.4 years) who initiated weekly oral alendronate therapy.
Using a 60-day refill gap, the 1-year discontinuation rate was 49.6% [95% confidence interval (CI) 48.8–50.4%]; this increased to 58.0% (CI 57.2–58.8%) with a 30-day gap and decreased to 42.2% (CI 41.1–43.0%) with a 120-day gap. Among those who discontinued therapy, about one-third restarted alendronate or another osteoporosis drug within 6 months. Baseline factors associated with alendronate discontinuation included prior bone mineral density testing [adjusted odds ratio (OR) 0.64, CI 0.60–0.69], prior postmenopausal hormone therapy (OR 0.78, CI 0.73–0.84), prior high-dose oral glucocorticoid therapy (OR 1.26, CI 1.05–1.51), prior gastrointestinal diagnoses (OR 1.21, CI 1.09–1.36), and high number of therapeutic classes of prescriptions filled in the prior year (OR 1.21, CI 1.10–1.32), although the final model had limited explanatory power.
We conclude that apparent discontinuation rates are high within 1 year after treatment initiation, although a subset of women appears to restart bisphosphonate or other osteoporosis therapy. Because intermittent use and/or poor adherence is common, discontinuation rates based on data from administrative databases are sensitive to the refill gap length. In addition, we identified no clinical factors highly predictive of discontinuation.
KeywordsAlendronate Postmenopausal women
This work was supported by funding from Novartis Pharmaceuticals Corporation. J.C.L. is a scholar in the Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) Program sponsored by the National Institute of Child Health and Human Development and the Office of Research on Women’s Health at the National Institutes of Health (9 K12HD052163-06).
- 1.Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541PubMedCrossRefGoogle Scholar
- 2.Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249CrossRefGoogle Scholar
- 3.Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280:2077–2082PubMedCrossRefGoogle Scholar
- 4.Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA 282:1344–1352PubMedCrossRefGoogle Scholar
- 5.Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 11:83–91PubMedCrossRefGoogle Scholar
- 10.Ettinger B, Earnshaw SR, Graham CN, Amonkar MM, Baran RW (2005) Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: Implications of improved persistence with ibandronate. J Bone Miner Res 20(Suppl 1):S398–S399 (abstract M361)Google Scholar
- 11.MarketScan (2000) MEDSTAT Group Inc. Ann Arbor, MIGoogle Scholar
- 14.Miller RG, Bolognese M, Worley K, Solis A, Sheer R (2004) Incidence of gastrointestinal events among bisphosphonate patients in an observational setting. Am J Manag Care 10:S207–S215Google Scholar
- 17.Recker RR, Gilmore A, Hebborn A, Takemoto S (2005) Bisphosphonate dosing regimens influence adherence to treatment in women with postmenopausal osteoporosis. Presented at the 87th Annual Meeting of the Endocrine Society, June 4–7, 2005, San Diego CA, abstract P3–P372Google Scholar
- 18.Boccuzzi SJ, Foltz SH, Omar MA, Kahler KH (2005) Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Presented at the 87th Annual Meeting of the Endocrine Society, June 4–7, 2005, San Diego CA, abstract P1–P438Google Scholar
- 19.Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N (1998) Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Managed Care Pharm 4:488–492Google Scholar
- 20.Papaioannou A, Ioannidis G, Adachi JD, Sebaldt RJ, Ferko N, Puglia M, Brown J, Tenenhouse A, Olszynski WP, Boulos P, Hanley DA, Josse R, Murray TM, Petrie A, Goldsmith CH (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14:808–813PubMedCrossRefGoogle Scholar
- 24.Silverman S, Siris E, Abbott T, Barr C, Harris S, Rosen C (2005) Adherence to bisphosphonate therapy is associated with decreased nonvertebral osteoporotic fracture risk. J Bone Miner Res 20(Suppl 1):S286 (abstract SU417)Google Scholar